Next Article in Journal
Dual Core-Shell Loaded Lipid-Polymer Hybrid Nanoparticles as Combination Anti-Infective Delivery Platforms
Previous Article in Journal
A Systematic Review of Advanced Drug Delivery Systems: Engineering Strategies, Barrier Penetration, and Clinical Progress (2016–April 2025)
Previous Article in Special Issue
PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal Clearance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 18
Issue 1
10.3390/pharmaceutics18010012
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceutics 2025, 17(4), 500.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500

by
Monica E. Susilo
1,*,†,
Stephan Schaller
2,†,
Luis David Jiménez-Franco
2,
Alexander Kulesza
2,
Wilhelmus E. A. de Witte
2,
Shang-Chiung Chen
1,
C. Andrew Boswell
1,
Danielle Mandikian
1 and
Chi-Chung Li
1,*
1
Genentech, Inc., South San Francisco, CA 94080, USA
2
ESQlabs GmbH, Am Sportplatz 7, 26683 Saterland, Germany
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2026, 18(1), 12; https://doi.org/10.3390/pharmaceutics18010012
Submission received: 10 October 2025 / Revised: 25 November 2025 / Accepted: 1 December 2025 / Published: 22 December 2025
(This article belongs to the Special Issue Development of Physiologically Based Pharmacokinetic (PBPK) Modeling)
Browse Figure
Versions Notes
Error in Figure
In the original publication [1], there was a mistake in Figure 1 as published. An incorrect version of Figure 1 was included in the publication. This was purely a graphical error and does not affect the model or results. The figure legend for Figure 1 has been updated to rename the internalization rate constant (kint) as the elimination rate constant (kelim), given the definition of internalization which involves endocytosis. The corrected Figure 1 and its legend appear below:
Text Correction
There was an error in the original publication, where the parameters kelim and kint were incorrectly referenced in Section 2.3.
A correction has been made to Section 2.3, paragraph 3.
“Simulation scenarios for model calibration were defined according to the experimental setup in [9]. The CD3-related parameters (krec, kelim, kon, koff) and HER2 parameters (ksyn, kdeg, kelim, kon, koff) were fitted in a hybrid, stepwise approach, using both manual adjustments and gradient-based parameter identification algorithms (Levenberg–Marquardt) included in the OSP Suite.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Susilo, M.E.; Schaller, S.; Jiménez-Franco, L.D.; Kulesza, A.; de Witte, W.E.A.; Chen, S.-C.; Boswell, C.A.; Mandikian, D.; Li, C.-C. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. [Google Scholar] [CrossRef] [PubMed]
Pharmaceutics 18 00012 g001
Figure 1. Schematic representation of (A) T-cell PBPK model and (B) T-cell-TCB-target cell synapse formation model. T-cell transmigration from vascular to extravascular space is indicated by the green arrow. ksyn refers to the zero-order target synthesis rate; kdeg, krec, and kelim refer to the first-order degradation, recycling, and elimination rate contants of the target and the TCB-target complexes, respectively; koff refers to the first-order TCB-target dissociation rate constants; and kon refers to the second-order TCB-target association rate constants.
Figure 1. Schematic representation of (A) T-cell PBPK model and (B) T-cell-TCB-target cell synapse formation model. T-cell transmigration from vascular to extravascular space is indicated by the green arrow. ksyn refers to the zero-order target synthesis rate; kdeg, krec, and kelim refer to the first-order degradation, recycling, and elimination rate contants of the target and the TCB-target complexes, respectively; koff refers to the first-order TCB-target dissociation rate constants; and kon refers to the second-order TCB-target association rate constants.
Pharmaceutics 18 00012 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Susilo, M.E.; Schaller, S.; Jiménez-Franco, L.D.; Kulesza, A.; de Witte, W.E.A.; Chen, S.-C.; Boswell, C.A.; Mandikian, D.; Li, C.-C. Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. Pharmaceutics 2026, 18, 12. https://doi.org/10.3390/pharmaceutics18010012

AMA Style

Susilo ME, Schaller S, Jiménez-Franco LD, Kulesza A, de Witte WEA, Chen S-C, Boswell CA, Mandikian D, Li C-C. Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. Pharmaceutics. 2026; 18(1):12. https://doi.org/10.3390/pharmaceutics18010012

Chicago/Turabian Style

Susilo, Monica E., Stephan Schaller, Luis David Jiménez-Franco, Alexander Kulesza, Wilhelmus E. A. de Witte, Shang-Chiung Chen, C. Andrew Boswell, Danielle Mandikian, and Chi-Chung Li. 2026. "Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500" Pharmaceutics 18, no. 1: 12. https://doi.org/10.3390/pharmaceutics18010012

APA Style

Susilo, M. E., Schaller, S., Jiménez-Franco, L. D., Kulesza, A., de Witte, W. E. A., Chen, S.-C., Boswell, C. A., Mandikian, D., & Li, C.-C. (2026). Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. Pharmaceutics, 18(1), 12. https://doi.org/10.3390/pharmaceutics18010012

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop